<DOC>
	<DOC>NCT00972595</DOC>
	<brief_summary>This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.</brief_summary>
	<brief_title>Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>If female, subject is not pregnant or breastfeeding Subject has been a nonsmoker for at least 6 months Subject is in good health Subject has a history of high blood pressure, asthma, other pulmonary disease, Gastrointestinal (GI) abnormalities/peptic ulcers, or cardiovascular, liver, neurologic, or kidney disease Subject is a habitual and heavy consumer of caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>